Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03983538 · ClinicalTrials.gov registry record
Mathematical Modeling to Predict Response to Neoadjuvant Chemotherapy in Breast Cancer
A clinical trial, sponsored by New Mexico Cancer Research Alliance.
- Completed
- Registry status
- 10
- Enrollment target
NCT03983538: Completed study, sponsored by New Mexico Cancer Research Alliance.
NCT03983538 is a clinical trial that has completed, run by New Mexico Cancer Research Alliance. The registered enrollment target is 10 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03983538 has completed, sponsored by New Mexico Cancer Research Alliance.
- COMPLETED
- Registry status
- 10 participants
- Enrollment target
Study Summary
This is a feasibility study evaluating the use of a mathematical model to predict response to standard neoadjuvant anthracycline / taxane based chemotherapy in patients with breast cancer.
Primary Outcome
To assess the feasibility of using diagnostic needle core biopsy to mathematically predict ƒkill-path (fraction of tumor cells killed calculated using data obtained from histopathology) in 10 women with stage II-III Her2-negative, Estrogen Receptor (ER) positive or negative infiltrating ductal carcinoma (IDC) of the breast undergoing neoadjuvant anthracycline / taxane based chemotherapy. Calculation of patient specific distribution of liver portal radii or characteristic vessel radius (rb), BVF
Interventions
- OTHER Mathematical modeling to predict response to chemotherapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2015-06-02 |
| Est. Completion | 2018-01-28 |
What the finished NCT03983538 record still lists
NCT03983538 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 10 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which Mathematical modeling to predict response to chemotherapy is the first listed.
NCT03983538 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03983538 about?
NCT03983538 is a clinical study titled "Mathematical Modeling to Predict Response to Neoadjuvant Chemotherapy in Breast Cancer". This is a feasibility study evaluating the use of a mathematical model to predict response to standard neoadjuvant anthracycline / taxane based chemotherapy in patients with breast cancer.
What is the current status of trial NCT03983538?
This trial is currently completed. The enrollment target is 10 participants. The study started on 2015-06-02. Estimated completion is 2018-01-28.
What interventions are being tested in trial NCT03983538?
The interventions under investigation include: Mathematical modeling to predict response to chemotherapy (OTHER).
Who is sponsoring clinical trial NCT03983538?
This trial is sponsored by New Mexico Cancer Research Alliance, which has 66 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00623389 · 10 participants · NA
Evaluation of an Advanced Lower Extremity Neuroprostheses
- NCT01241864 · 10 participants · Phase 2
Islet Transplantation in Type 1 Diabetic Kidney Allograft
- NCT01293214 · 10 participants · NA
Vascularized Composite Allotransplantation for Multiple Extremity Amputations
- NCT01474148 · 10 participants · NA
A Neuroprosthesis for Seated Posture and Balance
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI